© 2021 MJH Life Sciences and Urology Times. All rights reserved.
© 2021 MJH Life Sciences™ and Urology Times. All rights reserved.
April 19, 2021
The applications are supported by data from the EV-301 and EV-201 trials.
April 16, 2021
Galsky highlights final OS data from the IMvigor130 trial, along with an exploratory analysis examining outcomes by type of chemotherapy used.
April 13, 2021
The FDA has approves sacituzumab govitecan (Trodelvy) for patients with prevviously treated locally advanced or metastatic urothelial cancer.
April 06, 2021
Michael Devitt, MD, discusses the choice between erdafitinib and enfortumab vedotin in previously treated urothelial carcinoma.
March 30, 2021
The panel recommended adding data from the phase 3 KEYNOTE-361 trial to the label for pembrolizumab for its indication for patients with advanced or metastatic urothelial carcinoma.
March 26, 2021
The application is supported by findings from the phase 3 EV-301 trial.
March 24, 2021
“This study represents the most comprehensive analysis to date of tumor mutation burden as a biomarker for response to immune checkpoint blockade,” according to lead study author Daniel J. McGrail, PhD.
Watch the on-demand video of Urology Times' March 2021 Around the Practice.
March 17, 2021
Investigational agents on the horizon include Vicineum, nadofaragene firadenovec, and N-803 (Anktiva).
March 12, 2021
The treatment paradigm in upper tract urothelial carcinoma (UTUC) is rapidly evolving, particularly with the FDA approving mitomycin gel (Jelmyto) as the first therapy to treat low-grade UTUC.
Case study of a patient with muscle-invasive bladder cancer.
March 10, 2021
A search of a legal database found 42 cases related to cystectomy over a 30-year period.
March 08, 2021
The safety and efficacy of the locally administered fusion protein were assessed in the phase 3 VISTA trial.
The investigational padeliporfin ImPACT platform involves the intravenous delivery of the photosensitive drug padeliporfin, which is then activated by a non-thermal light delivery system.
The withdrawal comes after the confirmatory phase 3 IMvigor211 study missed its primary end point.
March 05, 2021
“The role of genomic testing in bladder is expanding almost every year,” says Faltas.
March 03, 2021
Treatment following progression on chemotherapy and an immune checkpoint inhibitor remains an unmet medical need.
Shaakir Hasan, DO, discusses socioeconomic characteristics associated with the diagnosis and management of bladder cancer.